EMA

#Diamond Pharma Services #EMA #Gene therapy #Marketing approval authorisation

Diamond Pharma Services supports MAA for ocular gene therapy

Diamond Pharma Services has provided EU regulatory, pharmacovigilance, quality and compliance support to GenSight Biologics including the preparation, authoring support, agency communication and submission of GenSight’s first marketing authorisation application (MAA) to the European Medicines Agency (EMA), for its novel ocular gene therapy LUMEVOQ.  The EMA decision is expected in… Read More

#News